HONG KONG, Aug 29, 2024 – (ACN Newswire) – CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. The meningococcal conjugate vaccines demonstrated robust growth, particularly the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), known as MCV4 or Menhycia®. As…
Check Also
CELEBRATING SONGKET IN THE UNITED STATES, Business Wires News
WASHINGTON, Oct. 1, 2024 /PRNewswire/ — Songket, Malaysia’s prized traditional textile, will take center stage …